A Microfluidic Liver Chip for Evaluating Idiosyncratic Drug-Induced Liver Injury

Overview

Idiosyncratic drug-induced liver injury (iDILI) is a rare but potentially severe form of liver damage that occurs as a result of certain medications. It is characterized by liver inflammation and damage that is not directly caused by the toxic effects of the drug, but rather by an immune response to the drug. Previous iDILI research such as low-dose LPS animal models are not able to promptly detect hepatic inflammation and the parameters of these models often change with the drug being studied. In this study, microfluidic technology was employed to create a laminated liver chip containing HepG2, U937 macrophages, LX-2, and EA.hy926 cells, as well as an inflammation model, and evaluated the known iDILI drug troglitazone. The results of this research demonstrate that the combination of troglitazone and LPS significantly increases liver cell damage and the production of inflammatory factors TNF-α and IL -6. This evaluation method, which mimics the microenvironment of the human liver, can partially compensate for the limitations of animal models and in vitro models. The chip also allows for the examination of different inflammatory conditions and the impact of drugs on the liver, providing a more comprehensive understanding of iDILI. Overall, this research presents a new and promising method for the study of iDILI, which can aid in the development of safer drugs and treatments for liver injury. CONNECTICUT

Competition history

• JSHS 2023 Category not listed

Resources

• National JSHS abstract book ↗

Related projects

Closest projects by meaning, across every fair and year in the corpus.